Compare AMCX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | CAPR |
|---|---|---|
| Founded | 1980 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.0M | 584.9M |
| IPO Year | 2011 | 2011 |
| Metric | AMCX | CAPR |
|---|---|---|
| Price | $9.11 | $8.36 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $9.50 | ★ $27.25 |
| AVG Volume (30 Days) | 687.2K | ★ 3.6M |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,311,801,000.00 | N/A |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | N/A | $85.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.47 | $2.96 |
| 52 Week High | $12.93 | $40.37 |
| Indicator | AMCX | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 50.24 |
| Support Level | $7.34 | $7.78 |
| Resistance Level | $10.58 | $10.42 |
| Average True Range (ATR) | 0.49 | 1.01 |
| MACD | 0.23 | 0.23 |
| Stochastic Oscillator | 69.41 | 45.99 |
AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.